En route to BLA fil­ing, Ac­tini­um de­tails PhI­II win for tar­get­ed ra­dio­ther­a­py in acute myeloid leukemia

Ac­tini­um Phar­ma­ceu­ti­cals has spelled out the full Phase III da­ta for its lead tar­get­ed ra­dio­ther­a­py — one that ex­ecs say presents a “prac­tice ex­pand­ing op­por­tu­ni­ty” in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER